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© 2009 The Japan Society of Histochemistry and Cy- Growth hormone (GH)-producing adenomas (GHomas) are one of the most frequently-
occurring pituitary adenomas. Differentiation of hormone-producing cells in the pituitary
gland is regulated by transcription factors and co-factors. The transcription factors include
Pit-1, Prop-1, NeuroD1, Tpit, GATA-2, SF-1. Aberrant expression of transcription factors such
as Pit-1 results in translineage expression of GH in adrenocorticotropic hormone-producing
adenomas (ACTHomas). This situation has been substantiated by GFP-Pit-1 transfection
expression in the AtT20 cell line. Experimentally, GHomas have been induced in GH-
releasing hormone (GHRH) or Prop-1 transgenic animals. Immunohistochemical detection
of somatostatin receptor (SSTR2a) has recently emphasized their role in the response of
GHomas to somatostatin analogue therapy. In this review, the advances in technology and
their contribution to cell biology and medical practice are discussed.
Key words: pituitary adenoma, transcription factor, cell lineage, functional differentiation, pituitary
hormones
I. Introduction
It is well known that the pituitary glands produce
and secrete six different hormones: growth hormone
(GH), prolactin (PRL), thyroid-stimulating hormone (TSH),
adrenocorticotropic hormone (ACTH), follicle-stimulating
hormone (FSH) and luteinizing hormone (LH). While FSH
and LH are produced in the same cells, GH, PRL, TSH and
ACTH are generally produced in different cells. In some cell
types, the coexpression of GH and PRL in the same cells has
been detected by immunohistochemistry. The regulation of
the genes encoding these hormones is known to be carried
out by transcription factors and co-factors (Fig. 1, Fig. 2,
Table 1). Immunohistochemistry has shown that GH-pro-
ducing cells (GH cells) predominate in the pituitary glands
both in humans and rodents. In humans, GH cells frequently
also produce the alpha subunit of glycoprotein hormones,
TSH, FSH/LH. GHomas are one of the most frequent ade-
nomas treated by transsphenoidal approaches. They are
frequently associated with acromegaly and other clinical
complications. Interesting pathological characteristics of
GHomas include (1) fibrous (keratin) bodies, (2) occasional
concomitant production of ACTH, and (3) gangliocytoma
(GHRH-GH production).
This review will outline the role of GH cells and
GHomas as models for the implementation of recent techni-
cal advances in the areas of pituitary pathology and research.
II. Morphology of GH Cells
In rodents and humans, GH cells are distributed in the
lateral lobes of the pituitary and possess a characteristicOsamura et al. 96
round shape. They contain eosinophilic cytoplasm as dem-
onstrated by H&E staining (Fig. 3A). Immunohistochemis-
try (IHC) shows that frequently exhibit dense cytoplasmic
staining in the cytoplasm (Fig. 3B). Moreover, electron mi-
croscopy shows many large round electron dense secretory
granules (SG) in these cells [21]. Nakane first showed that
GH cells are in close contact with ACTH cells in the rat
pituitary glands [17], and we have also observed a similar
structural relationship in human pituitary glands (Fig. 3C).
Matsuno et al. have reported, by double staining with IHC
and non-radioisotopic in situ hybridization (ISH), that GH
mRNA is localized in the polyribosomes on the rough endo-
plasmic reticulum (RER) and GH protein in the predominant
SGs in the cytoplasm [13]. In contrast, PRL-expressing
cells possess prominent RER and smaller numbers of SGs.
It is now generally agreed that GH cells produce smaller
Fig. 1. Schematic illustration of three cell lineages, GH-PRL-TSH, ACTH and FSH/LH, which are regulated by a combination of transcription
factors and co-factors (rodents). GH, growth hormone; PRL, prolactin; FSH, follicle-stimulating hormone; LH, luteinizing hormone; TSH,
thyroid-stimulating hormone; ACTH, adrenocorticotropic hormone (modified from Osamura et al.) [22].
Fig. 2. Schematic illustration of three cell lineages in human pituitary glands, GH-PRL-TSH, ACTH and FSH/LH, which are similarly defined
by a combination of transcription factors and co-factors to those in rodents (Fig. 1). Note that ACTH is the first hormone to appear and that the
human pituitary adenomas express the functional differentiation according to the normal process of development. It is also characteristic to see
the co-localization of GH and αSU in the pituitary cells and in the adenomas (modified from Osamura et al.) [24].Growth Hormone-producing Cells and Pituitary Adenomas 97
Table 1. Pituitary related transcription factors in development 
Modified from Savage et al. 2003 [28].
Transcription Factor Related Hormone Predicted Function
PTX1 ACTH, LH/FSH/GH, PRL, TSH Important for early pituitary development and later activation of hormone gene
PROP1 GH, PRL, TSH, LH/FSH Important for somatotrope, lactotrope, thyrotrope and gonadotrope development
FOXL2 αSU, Express in early pituitary and related to differentiation of αSU positive cells
EGR1 LH/FSH Important in gonadotrope and somatotrope development
NEUROD1 ACTH Important in POMC gene regulation in corticotropes
TPIT ACTH Important for POMC gene expression in the corticotrope and melanotrope
PIT1 GH, PRL, TSH Need for somatotrope, lactotrope and thyrotrope development
GATA2 LH/FSH, TSH Regulation of gonadotrope and thyrotrope cell differentiation
SF1 LH/FSH Required for gonadotrope development
ERα PRL Important in PRL and gonadotropin gene expression and lactotrope cell growth
GHRH-R GH Regulation of somatotrope differentiation
Fig. 3. Demonstration of hormone-producing cells in the normal pituitary glands, human (A–C) and rat (D). A: H&E stained anterior lobe with
many round hormone-producing cells. B: The same section as A. The perivascular eosinophilic cells (in A) are positively stained for GH.
C: GH cells (brown) and ACTH cells (blue) are present in close proximity to one another. D: FSH/LH cells (brown) and PRL cells (blue) are
present in tight conjunction (left). These hormone-producing cells contain many dense-cored secretory granules (right).Osamura et al. 98
amounts of GH and secrete very gradually, whereas PRL-
positive cells can produce and secrete PRL very rapidly by
turning-over the SG. General questions which arise from
these observations include (1) how specific cells produce
GH and other hormones and (2) how GH-expressing cells
result in one of the most frequently occurring pituitary ade-
nomas in humans. One of the characteristic features of the
human pituitary glands is that many adult GH cells also
contain α-subunit (SU) in the cytoplasm and in the same
SG [19], and occasionally GH cells are also co-localized
with FSHβSU. Therefore, it appears that human GH cells
may contain factors required for the differentiation toward
gonadotropin-producing cells. GH and PRL are also occa-
sionally co-expressed in GH cells as mentioned earlier.
III. Production of GH by Specific Pituitary 
Cells: Transcriptional Mechanism for GH 
in Development and Differentiation
The mechanism of this differentiation toward GH was
first suggested by the cloning of the pituitary-specific tran-
scription factor-1 (Pit-1) by Adler et al. and Bodner and
Karin [1, 2]. Pit-1 was shown to regulate the functional dif-
ferentiation of GH-, PRL- and TSH-producing cells. This
stimulated the cloning of many pituitary-related transcrip-
tion factors, such as Prop-1, NeuroD1 [32] and Tpit [11].
Known pituitary-related transcription factors are shown in
Table 1. These transcription factors mediate the differentia-
tion of pituitary cells into one of three cell lineages: (1) the
Fig. 4. Demonstration of hormones and transcription factor Pit-1 in GH-producing pituitary adenoma (GHoma). A: H&E stained GHoma dem-
onstrating many eosinophilic round tumor cells. These tumor cells are positive for GH (B), PRL (C). D: Many round dense secretory granules
are observed in the cytoplasm. E: Double immunohistochemical staining indicates the GH+ tumors cells and αSU+ tumor cells. Some tumor
cells demonstrate co-localization of GH and αSU (arrows). F: Many tumor cells show intense nuclear staining for Pit-1. The lower scheme
indicates the proposed development of GH+αSU+cells.Growth Hormone-producing Cells and Pituitary Adenomas 99
Pit-1 cell lineage (GH, PRL, TSH), (2) the SF-1 lineage
(FSH/LH); and (3) the NeuroD1 lineage (ACTH, proopio-
melanocortin (POMC)) [20]. αSU is one of the earliest
hormones to play a role in the development of the pituitary
(embryonic day 11) [34]. FOXL2 [7], and possibly Lhx3
play a role in regulating the expression of αSU in rodents.
As the expression profile of transcription factors in pi-
tuitary adenomas is generally similar to those in the normal
anterior pituitary cells, GHomas, as will be described later,
express Pit-1.
IV. Pathology of GH-producing Pituitary 
Adenomas
GH-producing adenomas are one of the most frequent
human pituitary adenomas, and are commonly associated
with acromegaly. Occasionally, however, they occur with-
out clinical symptoms and are designated as “silent” GH cell
adenomas. The 2004 World Health Organization (WHO)
classification classifies them into densely granulated or
sparsely granulated GHomas. Morphologically, the tumor
cells are round and eosinophilic (Fig. 4A), and electron
microscopy shows the presence of many electron-dense
granules (Fig. 4D).
Immunohistochemistry
Many GHomas exhibit diffuse GH staining in their
cytoplasm (Fig. 4B). Approximately 60% of the cases show
the concomitant localization of αSU and PRL (Fig. 4C, 4E),
as shown by immunohistochemical double staining [21]
(Fig. 4E). Many of the cases of sparsely granulated ade-
nomas demonstrate fibrous bodies as demonstrated next.
Fibrous bodies
Immunohistochemistry of sparsely granulated GHomas
frequently shows spherical aggregates (inclusions) of inter-
Fig. 5. A case of pituitary adenoma in Cushing’s disease. Translineage expression of ACTH and GH. By H&E staining, many smaller and com-
pact tumor cells are observed (Inset A). Many tumor cells show immunohistochemical co-localization of ACTH and GH (Inset B arrow). Immu-
nohistochemically, many tumor cells show nuclear staining for NeuroD1 (A- for ACTH differentiation) and Pit-1 (B- for GH differentiation).
Schematic drawing indicates the “translineage” differentiation of ACTH and GH in the pituitary adenoma (*).Osamura et al. 100
mediate filaments and it has been demonstrated that these
fibrous bodies are composed of various types of keratin
[27]. Takei et al. reported that GHomas with fibrous bodies
are frequently macroadenomas (diameter >1 cm) [29].
Gangliocytomas & metastatic GHRH-producing pancreatic 
neuroendocrine carcinoma
On rare occasions, microscopy of intrasellar tumors
identifies a mixture of pituitary adenoma cells and ganglion
cells. Immunohistochemically, these ganglion cells are pos-
itive for GHRH and the pituitary adenoma cells are positive
for GH [9]. Some of the ganglion cells appear to be also
positive for GH.
In some cases, GHRH-producing neuroendocrine tu-
mors occur in the pancreas and bronchus. We have previous-
ly reported a case of GHRH-producing metastatic pancreatic
neuroendocrine carcinoma (NEC) showing hyperplastic GH
cell in an enlarged pituitary gland [26]. While similar cases
have been reported in the literature, the high GHRH in these
cases was caused by remote tumors in the lung and pancreas
[5].
V. Transcription Factors and Functional 
Differentiation in GHomas
We, as well as other investigators, have reported that
human GHomas express a combination of transcription
factors similar to those in the non-neoplastic “normal”
pituitary glands, which have been reported in rodents and
human. It has been elucidated that human GHomas express
Pit-1 by immunohistochemistry (IHC) and in situ hybridiza-
tion (ISH) and other molecular methods such as RT-PCR or
real time RT-PCR. GHRH-receptor (GHRH-R) and other co-
factors have also been reported in GHomas. Pit-1 has been
identified in PRLomas and TSHomas [15], and estrogen
receptor (ER) and GATA-2 have been demonstrated in
PRLomas and TSHomas, respectively. We also have re-
ported that non-canonical Wnt4 signaling is related to the
Pit-1 lineage in human adenomas, GHomas, PRLomas and
TSHomas [16]. In the case of GHomas, our questions were
as follows: (1) Does Pit-1 expression correlate with GH pro-
duction? (2) What is the mechanism for the production of
PRL in GHomas? (3) How are ACTH and GH expressed
aberrantly in human adenomas?
Fig. 6. Experimental induction of GH by GFP-Pit-1 gene transfection in AtT20 cells. The cells with nuclear fluorescence were collected in “live
state” by laser microdissection (PALM Carl Zeiss). Compared with those having cytoplasmic fluorescence, the cells with nuclear fluorescence
(yellow star) demonstrated exclusive expression of Pit-1mRNA and GHmRNA by quantitative RT-PCR (upper panel).Growth Hormone-producing Cells and Pituitary Adenomas 101
Does the amount of Pit-1 expression correlate with GH 
production? Use of siRNA technology
IHC and in situ hybridization have been used to demon-
strate that, GHomas express Pit-1, which in turn regulates
PRL and TSH expression. Using siRNA technology, Miyai
et al. showed that the amount of GH protein expression is
correlated with the amount of Pit-1 protein in GHomas [14].
The other co-factors for Pit-1 include GHRH-R, the gene for
which has a Pit-1 binding site in its promoter region. This
co-factor is probably related with the more specific expres-
sion of GH. In the case of the TSH gene, the synergistic ac-
tion between GATA-2 and Pit-1 has been demonstrated [33].
What is the mechanism for the production of PRL in 
GHomas? Use of Laser capture microdissection (LCM) 
technology
Laser capture microdissection (LCM) has been used
to analyze the expression of ERα and ERβ in GHomas.
GHoma cells which exhibited PRL expression by IHC
showed ERα mRNA expression by RT-PCR, which may
indicate the involvement of ERα in the expression of PRL
in GHomas cells. It is also known that one of eight Pit-1
binding sites in the promoter region of PRL gene is in very
close vicinity to an ER binding site [31].
How are trans-lineage ACTH and GH expressed in the same 
human adenomas? Aberrant transcription factors and pit-1 
transfection with GFP technology
Aberrant expression transcription factors
Multiple hormone production usually occurs for hor-
mones or hormone subunits in the same lineages: i.e. the
Pit-1 lineage (GH, PRL, TSH), the SF-1 lineage (FSH/LH)
and the NeuroD1/Tpit lineage (ACTH/POMC). Very rarely,
GHomas produce ACTH or ACTHomas produce GH, and
this phenomenon has been designated as “aberrant” trans-
lineage differentiation of the tumor cells.
GHomas with ACTH production
On rare occasions, patients with acromegaly induced
by GHomas also show elevated serum ACTH levels. In this
situation, the tumor cells show co-expression of Pit-1 and
NeuroD1, which also constitutes “aberrant” expression of
transcription factors resulting in the translineage differentia-
tion of the cells, and is probably related to the neoplastic
process. On the other hand, ACTHomas in patients with
Cushing’s disease occasionally show GH production. This
is also induced by the aberrant expression of Pit-1 in the
NeuroD1-regulated tumor cells (Fig. 5). The latter condi-
tion was reproduced by transfection of Pit1 in the ACTH-
producing cell line, AtT20 [10] as described below.
Fig. 7. Experimental model for GH-producing pituitary adenoma induced in the hGHRH transgenic mice. The pituitary tumor cells in hGHRH
transgenic mice are immunohistochemically positive for GH, PRL and TSH. They are also positive for GHRH and Pit-1 [23].Osamura et al. 102
Induction of GH mRNA or GH protein by transfection of 
Pit-1: Use of GFP technology in conjunction with laser 
capture microdissection technology
In order to reproduce the human condition of the aber-
rant expression of GH in ACTH adenomas, an in vitro ex-
perimental model was designed by transfecting a Pit1-GFP
construct into the Pit-1-negative/GH negative AtT20 cell
line [10]. AtT20 cells with nuclear GFP expression showed
Pit-1 mRNA and GH mRNA by RT-PCR indicating that Pit-
1 binding to DNA induced GH expression (Fig. 6).
By combining GFP and “live cell” laser capture micro-
dissection (LCM) (PALM, Carl Zeiss) technologies, cells
exhibiting GFP in the nuclei expressed higher amounts of
GH mRNA than those with cytoplasmic GFP, as measured
by real time RT-PCR. These experiments indicate that aber-
rant expression of additional transcription factors could in-
duce translineage expression of hormones in functionally
committed tumor cells. The molecular mechanism for the
aberrant expression of transcription factors remains to be
further investigated.
VI. Experimental GH-producing Adenomas
Experimental models for GHomas have been reported
by transgenic animal models, one for GHRH and the other
for Prop-1.
GHRH transgenic mice
In human GHRH transgenic mice, the pituitaries were
enlarged and histologically exhibited GH-producing ade-
nomas and diffusely increased hyperplastic GH cells in the
pituitary glands [23]. In particular, the tumors contained
nodules which express only GH and PRL and not ACTH or
FSH/LH (Fig. 7). Using a sensitive IHC method, Matsuno et
al. have reported that 15 of 25 GHomas were positive for
GHRH [12]. These findings indicate that at least some pro-
portion of GHomas could overexpress GHRH, resulting in
tumor formation.
Prop-1 transgenic mice
Camper et al. have reported the induction of pituitary
tumors, TSH producing as well as non-functional adenomas
[4]. In collaboration with Dr. Sally Camper (University of
Michigan USA), we have shown that Prop-1 transgenic mice
develop small adenomas in the pituitary glands, which were
positive for GH, PRL or TSHβ [6]. LCM showed that Pit-1
was overexpressed in the adenoma, indicating that it may be
related to the functional differentiation of the adenomas. The
question as to why some adenomas were GH positive and
other tumors were PRL- or TSH-positive still remains to be
further investigated. The non-neoplastic pituitary cells were
hyperplastic and expressed Prop-1 mRNA, even though the
adenoma cells did not express Prop-1. The disappearance of
Fig. 8. Immunohistochemical demonstration of somatostatin receptor2a (SSTR2a) in the GHoma (A), silent GHoma (B) and TSHoma (C). Note
the distinct staining of SSTR2a on the cell membrane of many tumor cells. These tumor cells are expected to respond to somatostatin analogue
treatment. The bottom scheme (D) demonstrates Pit-1 binding site in the promoter region of the mouse Sstr2 gene (modified from Olias G et al.)
[18].Growth Hormone-producing Cells and Pituitary Adenomas 103
Prop-1 mRNA may be attributable to the loss of αSU in the
adenoma cells during the progress of tumorigenesis, since
the construct was composed of Prop-1 and αSU.
VII. Medical Treatment of GHomas: Detection 
of Somatostatin Receptor (SSTRs)
GHomas are treated initially by transsphenoidal sur-
gery. In the cases of macroadenomas and residual tumors,
somatostatin analogs (SAs), octreotide or lanreotide, are
administered [3]. For this treatment, immunohistochemical
detection is typically performed in order to predict the
response of treatment. The somatostatin receptor (SSTR)
family is composed of five molecules: SSTR1, SSTR2a,
SSTR3, SSTR4, and SSTR5. The presence of SSTR2a has
been considered to be most important for the success of SA
treatment [25]. Immunohistochemically, SSTR2a has been
demonstrated on the cell membrane of the tumor cells
(Fig. 8A–8C). Moreover, Takei et al. have reported that the
association between an improved response to the preopera-
tive SA (octreotide) and enhanced immunohistochemical
SSTR2a positivity in patients with GHomas [30]. It has been
also shown that SSTR2a mRNA can be detected in formalin
fixed paraffin embedded (FFPE) sections [8].
VIII. Conclusions
In this review, the pathology, transcriptional mecha-
nism in the pituitary cells and pathogenesis of GH-produc-
ing adenomas (GHomas) were shown and discussed. It has
also been emphasized that the recent development of tech-
nologies such as GFP-transfection, transgenic animals and
laser capture microdissection has greatly contributed to the
elucidation of the molecular mechanisms of the expression
of particular genes. The treatment of GHomas with soma-
tostatin analogues has been shown to be of benefit in tumors
which display immunohistochemical positive staining for
SSTR2A on the cell membrane. It is expected that histo-
chemical techniques will contribute further to clarify the
molecular biology and pathology of GHomas, as well as to
stimulate therapeutic approaches.
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